Does the media prefer NEO or FLGT?

In the previous week, NeoGenomics had 2 more articles in the media than Fulgent Genetics. MarketBeat recorded 3 mentions for NeoGenomics and 1 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.60 beat NeoGenomics' score of -0.51 indicating that Fulgent Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeoGenomics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Fulgent Genetics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better earnings & valuation, FLGT or WGS?

GeneDx has higher revenue and earnings than Fulgent Genetics. GeneDx is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fulgent Genetics $322.67M 1.83 -$60.51M -$2.82 N/A GeneDx $427.54M 5.10 -$21.02M -$3.64 N/A

Is FLGT or WGS more profitable?

GeneDx has a net margin of -23.41% compared to Fulgent Genetics' net margin of -26.05%. GeneDx's return on equity of 4.12% beat Fulgent Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Fulgent Genetics -26.05% -4.93% -4.50% GeneDx -23.41% 4.12% 2.26%

Does the media refer more to FLGT or WGS?

In the previous week, GeneDx had 3 more articles in the media than Fulgent Genetics. MarketBeat recorded 4 mentions for GeneDx and 1 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.60 beat GeneDx's score of 0.82 indicating that Fulgent Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulgent Genetics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive GeneDx 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor FLGT or MD?

In the previous week, Pediatrix Medical Group had 2 more articles in the media than Fulgent Genetics. MarketBeat recorded 3 mentions for Pediatrix Medical Group and 1 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.60 beat Pediatrix Medical Group's score of 0.60 indicating that Fulgent Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulgent Genetics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Pediatrix Medical Group 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor FLGT or GRDN?

In the previous week, Guardian Pharmacy Services had 3 more articles in the media than Fulgent Genetics. MarketBeat recorded 4 mentions for Guardian Pharmacy Services and 1 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.60 beat Guardian Pharmacy Services' score of 0.98 indicating that Fulgent Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulgent Genetics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Guardian Pharmacy Services 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Fulgent Genetics (FLGT) Competitors

$21.48 +0.18 (+0.85%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$21.43 -0.05 (-0.23%)

As of 10/2/2026 07:30 PM Eastern

Compare

FLGT vs. NEO, WGS, MD, ADUS, and GRDN

Should you buy Fulgent Genetics stock or one of its competitors? Fulgent Genetics's main competitors and comparable companies include NeoGenomics (NEO), GeneDx (WGS), Pediatrix Medical Group (MD), Addus HomeCare (ADUS), and Guardian Pharmacy Services (GRDN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Fulgent Genetics compare to NeoGenomics?

NeoGenomics (NASDAQ:NEO) and Fulgent Genetics (NASDAQ:FLGT) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

NeoGenomics has a net margin of -6.77% compared to Fulgent Genetics' net margin of -26.05%. NeoGenomics' return on equity of -1.99% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeoGenomics	-6.77%	-1.99%	-1.21%
Fulgent Genetics	-26.05%	-4.93%	-4.50%

NeoGenomics has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market.

In the previous week, NeoGenomics had 2 more articles in the media than Fulgent Genetics. MarketBeat recorded 3 mentions for NeoGenomics and 1 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.60 beat NeoGenomics' score of -0.51 indicating that Fulgent Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeoGenomics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Fulgent Genetics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Fulgent Genetics has lower revenue, but higher earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeoGenomics	$727.33M	3.26	-$108.03M	-$0.40	N/A
Fulgent Genetics	$322.67M	1.83	-$60.51M	-$2.82	N/A

NeoGenomics currently has a consensus target price of $17.67, suggesting a potential downside of 4.35%. Fulgent Genetics has a consensus target price of $27.50, suggesting a potential upside of 28.03%. Given Fulgent Genetics' higher possible upside, analysts plainly believe Fulgent Genetics is more favorable than NeoGenomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeoGenomics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

98.5% of NeoGenomics shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 1.1% of NeoGenomics shares are held by company insiders. Comparatively, 36.2% of Fulgent Genetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

NeoGenomics beats Fulgent Genetics on 11 of the 16 factors compared between the two stocks.

How does Fulgent Genetics compare to GeneDx?

Fulgent Genetics (NASDAQ:FLGT) and GeneDx (NASDAQ:WGS) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

48.1% of Fulgent Genetics shares are held by institutional investors. Comparatively, 61.7% of GeneDx shares are held by institutional investors. 36.2% of Fulgent Genetics shares are held by insiders. Comparatively, 25.2% of GeneDx shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, GeneDx had 3 more articles in the media than Fulgent Genetics. MarketBeat recorded 4 mentions for GeneDx and 1 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.60 beat GeneDx's score of 0.82 indicating that Fulgent Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulgent Genetics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
GeneDx	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fulgent Genetics has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, GeneDx has a beta of 1.95, indicating that its share price is 95% more volatile than the broader market.

Fulgent Genetics presently has a consensus target price of $27.50, suggesting a potential upside of 28.03%. GeneDx has a consensus target price of $90.86, suggesting a potential upside of 24.31%. Given Fulgent Genetics' higher probable upside, research analysts clearly believe Fulgent Genetics is more favorable than GeneDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
GeneDx	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

GeneDx has higher revenue and earnings than Fulgent Genetics. GeneDx is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$322.67M	1.83	-$60.51M	-$2.82	N/A
GeneDx	$427.54M	5.10	-$21.02M	-$3.64	N/A

GeneDx has a net margin of -23.41% compared to Fulgent Genetics' net margin of -26.05%. GeneDx's return on equity of 4.12% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-26.05%	-4.93%	-4.50%
GeneDx	-23.41%	4.12%	2.26%

Summary

GeneDx beats Fulgent Genetics on 12 of the 17 factors compared between the two stocks.

How does Fulgent Genetics compare to Pediatrix Medical Group?

Fulgent Genetics (NASDAQ:FLGT) and Pediatrix Medical Group (NYSE:MD) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

48.1% of Fulgent Genetics shares are held by institutional investors. Comparatively, 97.7% of Pediatrix Medical Group shares are held by institutional investors. 36.2% of Fulgent Genetics shares are held by company insiders. Comparatively, 1.8% of Pediatrix Medical Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Pediatrix Medical Group has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Pediatrix Medical Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$322.67M	1.83	-$60.51M	-$2.82	N/A
Pediatrix Medical Group	$1.91B	1.10	$165.39M	$2.09	12.44

Fulgent Genetics currently has a consensus target price of $27.50, indicating a potential upside of 28.03%. Pediatrix Medical Group has a consensus target price of $26.60, indicating a potential upside of 2.34%. Given Fulgent Genetics' higher probable upside, research analysts plainly believe Fulgent Genetics is more favorable than Pediatrix Medical Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pediatrix Medical Group	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

Pediatrix Medical Group has a net margin of 8.96% compared to Fulgent Genetics' net margin of -26.05%. Pediatrix Medical Group's return on equity of 20.05% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-26.05%	-4.93%	-4.50%
Pediatrix Medical Group	8.96%	20.05%	8.15%

In the previous week, Pediatrix Medical Group had 2 more articles in the media than Fulgent Genetics. MarketBeat recorded 3 mentions for Pediatrix Medical Group and 1 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.60 beat Pediatrix Medical Group's score of 0.60 indicating that Fulgent Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulgent Genetics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Pediatrix Medical Group	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fulgent Genetics has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, Pediatrix Medical Group has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

Summary

Pediatrix Medical Group beats Fulgent Genetics on 10 of the 15 factors compared between the two stocks.

How does Fulgent Genetics compare to Addus HomeCare?

Fulgent Genetics (NASDAQ:FLGT) and Addus HomeCare (NASDAQ:ADUS) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

Fulgent Genetics presently has a consensus target price of $27.50, suggesting a potential upside of 28.03%. Addus HomeCare has a consensus target price of $129.33, suggesting a potential upside of 16.23%. Given Fulgent Genetics' higher possible upside, analysts clearly believe Fulgent Genetics is more favorable than Addus HomeCare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Addus HomeCare	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55

Fulgent Genetics has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Addus HomeCare has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market.

Addus HomeCare has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Addus HomeCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$322.67M	1.83	-$60.51M	-$2.82	N/A
Addus HomeCare	$1.48B	1.41	$95.91M	$5.70	19.52

Addus HomeCare has a net margin of 7.13% compared to Fulgent Genetics' net margin of -26.05%. Addus HomeCare's return on equity of 9.96% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-26.05%	-4.93%	-4.50%
Addus HomeCare	7.13%	9.96%	7.62%

In the previous week, Fulgent Genetics had 1 more articles in the media than Addus HomeCare. MarketBeat recorded 1 mentions for Fulgent Genetics and 0 mentions for Addus HomeCare. Fulgent Genetics' average media sentiment score of 1.60 beat Addus HomeCare's score of 0.00 indicating that Fulgent Genetics is being referred to more favorably in the media.

Company	Overall Sentiment
Fulgent Genetics	Very Positive
Addus HomeCare	Neutral

48.1% of Fulgent Genetics shares are owned by institutional investors. Comparatively, 95.3% of Addus HomeCare shares are owned by institutional investors. 36.2% of Fulgent Genetics shares are owned by insiders. Comparatively, 4.1% of Addus HomeCare shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Addus HomeCare beats Fulgent Genetics on 11 of the 17 factors compared between the two stocks.

How does Fulgent Genetics compare to Guardian Pharmacy Services?

Fulgent Genetics (NASDAQ:FLGT) and Guardian Pharmacy Services (NYSE:GRDN) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

Fulgent Genetics has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Guardian Pharmacy Services has a beta of 0.03, indicating that its share price is 97% less volatile than the broader market.

Guardian Pharmacy Services has a net margin of 4.50% compared to Fulgent Genetics' net margin of -26.05%. Guardian Pharmacy Services' return on equity of 29.97% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-26.05%	-4.93%	-4.50%
Guardian Pharmacy Services	4.50%	29.97%	16.18%

In the previous week, Guardian Pharmacy Services had 3 more articles in the media than Fulgent Genetics. MarketBeat recorded 4 mentions for Guardian Pharmacy Services and 1 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.60 beat Guardian Pharmacy Services' score of 0.98 indicating that Fulgent Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulgent Genetics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Guardian Pharmacy Services	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Guardian Pharmacy Services has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Guardian Pharmacy Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$322.67M	1.83	-$60.51M	-$2.82	N/A
Guardian Pharmacy Services	$1.45B	1.45	$49.22M	$1.03	41.09

48.1% of Fulgent Genetics shares are owned by institutional investors. 36.2% of Fulgent Genetics shares are owned by company insiders. Comparatively, 33.0% of Guardian Pharmacy Services shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Fulgent Genetics currently has a consensus price target of $27.50, suggesting a potential upside of 28.03%. Guardian Pharmacy Services has a consensus price target of $45.57, suggesting a potential upside of 7.69%. Given Fulgent Genetics' higher possible upside, equities analysts clearly believe Fulgent Genetics is more favorable than Guardian Pharmacy Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Guardian Pharmacy Services	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

Summary

Guardian Pharmacy Services beats Fulgent Genetics on 10 of the 16 factors compared between the two stocks.

Get Fulgent Genetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FLGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FLGT vs. The Competition

Export

Metric	Fulgent Genetics	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$586.08M	$9.59B	$7.14B	$13.17B
Dividend Yield	N/A	2.61%	2.53%	16.78%
P/E Ratio	-7.62	34.21	275.68	26.04
Price / Sales	1.83	5.39	662.25	102.14
Price / Cash	N/A	120.59	77.60	51.75
Price / Book	0.60	5.15	10.93	6.31
Net Income	-$60.51M	$315.68M	$3.51B	$362.16M
7 Day Performance	-3.24%	-2.59%	-2.00%	-1.66%
1 Month Performance	9.31%	-3.19%	-6.15%	-4.50%
1 Year Performance	-5.71%	7.93%	7.44%	2.06%

Fulgent Genetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FLGT Fulgent Genetics	3.4603 of 5 stars	$21.48 +0.8%	$27.50 +28.0%	-6.2%	$586.08M	$322.67M	N/A	1,315	Positive News
NEO NeoGenomics	0.9655 of 5 stars	$18.74 -2.9%	$17.67 -5.7%	+105.7%	$2.41B	$727.33M	N/A	2,500
WGS GeneDx	3.3874 of 5 stars	$75.79 -11.8%	$89.57 +18.2%	-37.7%	$2.26B	$427.54M	N/A	1,300	News Coverage Analyst Forecast
MD Pediatrix Medical Group	2.2503 of 5 stars	$26.03 +0.4%	$26.60 +2.2%	+52.1%	$2.11B	$1.91B	12.45	4,315
ADUS Addus HomeCare	3.2843 of 5 stars	$112.96 +0.9%	$129.33 +14.5%	-3.6%	$2.11B	$1.42B	19.82	50,659

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FLGT) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fulgent Genetics (FLGT) Competitors

FLGT vs. NEO, WGS, MD, ADUS, and GRDN

How does Fulgent Genetics compare to NeoGenomics?

Summary

How does Fulgent Genetics compare to GeneDx?

Summary

How does Fulgent Genetics compare to Pediatrix Medical Group?

Summary

How does Fulgent Genetics compare to Addus HomeCare?

Summary

How does Fulgent Genetics compare to Guardian Pharmacy Services?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGT vs. The Competition

Fulgent Genetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fulgent Genetics (FLGT) Competitors

FLGT vs. NEO, WGS, MD, ADUS, and GRDN

How does Fulgent Genetics compare to NeoGenomics?

Is NEO or FLGT more profitable?

Which has more risk & volatility, NEO or FLGT?

Does the media prefer NEO or FLGT?

Which has better valuation & earnings, NEO or FLGT?

Do analysts recommend NEO or FLGT?

Do institutionals and insiders hold more shares of NEO or FLGT?

Summary

How does Fulgent Genetics compare to GeneDx?

Do insiders & institutionals hold more shares of FLGT or WGS?

Does the media refer more to FLGT or WGS?

Which has more risk and volatility, FLGT or WGS?

Do analysts recommend FLGT or WGS?

Which has better earnings & valuation, FLGT or WGS?

Is FLGT or WGS more profitable?

Summary

How does Fulgent Genetics compare to Pediatrix Medical Group?

Do insiders and institutionals have more ownership in FLGT or MD?

Which has higher valuation & earnings, FLGT or MD?

Do analysts rate FLGT or MD?

Is FLGT or MD more profitable?

Does the media favor FLGT or MD?

Which has more risk and volatility, FLGT or MD?

Summary

How does Fulgent Genetics compare to Addus HomeCare?

Do analysts prefer FLGT or ADUS?

Which has more risk & volatility, FLGT or ADUS?

Which has stronger valuation and earnings, FLGT or ADUS?

Is FLGT or ADUS more profitable?

Does the media favor FLGT or ADUS?

Do insiders and institutionals hold more shares of FLGT or ADUS?

Summary

How does Fulgent Genetics compare to Guardian Pharmacy Services?

Which has more volatility & risk, FLGT or GRDN?

Is FLGT or GRDN more profitable?

Does the media favor FLGT or GRDN?

Which has better valuation & earnings, FLGT or GRDN?

Do insiders & institutionals hold more shares of FLGT or GRDN?

Do analysts prefer FLGT or GRDN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGT vs. The Competition

Fulgent Genetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools